Detail
Článek
Článek ve sborníku
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Assessment of the systemic effects of budesonide inhaled from Easyhaler and from Turbuhaler in healthy male volunteers [Hodnocení systémových účinků budesonidu inhalovaného z Easyhaleru a z Turbuhaleru u zdravých mužských dobrovolníků]

KM Hamalainen, M Granander, P Toivanen, A Malinen

. 2006 ; () : nestr..
. 2001 ; 95 (11) : 863-869.

Jazyk angličtina Země Česko, Velká Británie

Typ dokumentu klinické zkoušky, srovnávací studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14043176

The main objective of this study was to show dose-dependent equivalence in the systemic activity of budesonide 800 microg day(-1) and 1600 microg day(-1) delivered from either Easyhaler or Turbuhaler in healthy male subjects. This single-centre study was carried out according to a randomized, double-blind, double-dummy, five-way crossover design over a 9-week period. All subjects received 1 week of treatment with the following, in randomized order, with a washout week between each treatment: budesonide Easyhaler 800 microg day(-1) plus placebo Turbuhaler; budesonide Easyhaler 1600 microg day(-1) plus placebo Turbuhaler; placebo Easyhaler plus Pulmicort Turbuhaler 800 microg day(-1); placebo Easyhaler plus Pulmicort Turbuhaler 1600 microg day(-1); placebo Easyhaler plus placebo Turbuhaler. The final inhalation of study drug was performed at the study centre, where blood and urine samples were collected. Fifteen subjects were recruited and all completed the study. Mean serum cortisol AUC0-20 values (the primary outcome variable) were comparable for each device at the two dose levels, and met the defined criteria for equivalence (90% CI 0.8-1.25 for between-treatment difference). Budesonide 800 microg day(-1) caused minimal suppression of serum cortisol AUC0-20 values, Budesonide 1600 microg day(-1) statistically significantly suppressed serum cortisol AUC0-20 values compared with placebo. Mean morning serum cortisol values were within the reference range in al treatment groups. At a budesonide dose of 800 microg day(-1) mean urine cortisol/creatinine ratio was statistically significantly higher with Easyhaler than with Turbuhaler, but there was no significant difference between the devices at the 1600 microg day(-1) dose. Serum budesonide concentrations were equivalent for each device at both dose levels. Adverse drug reactions were infrequent and mild in nature and there were no clinically significant changes in laboratory safety variables. In conclusion, in healthy male volunteers, budesonide 800 microg day(-1) and 1600 microg day inhaled from Easyhaler had comparable systemic effects to the same doses inhaled via Turbuhaler.

Hodnocení systémových účinků budesonidu inhalovaného z Easyhaleru a z Turbuhaleru u zdravých mužských dobrovolníků

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc14043176
003      
CZ-PrNML
005      
20140124084021.0
007      
ta
008      
140123s2006 xr d f 000 0eng||
009      
PC
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng $b cze
044    __
$a xr $a xxk
100    1_
$a Hamalainen, K. M. $u Orion Pharma, Kuopio, Finland. kaisa.hamalainen@orionpharma.com
245    10
$a Assessment of the systemic effects of budesonide inhaled from Easyhaler and from Turbuhaler in healthy male volunteers / $c KM Hamalainen, M Granander, P Toivanen, A Malinen
246    31
$a Hodnocení systémových účinků budesonidu inhalovaného z Easyhaleru a z Turbuhaleru u zdravých mužských dobrovolníků
504    __
$a Literatura
520    9_
$a The main objective of this study was to show dose-dependent equivalence in the systemic activity of budesonide 800 microg day(-1) and 1600 microg day(-1) delivered from either Easyhaler or Turbuhaler in healthy male subjects. This single-centre study was carried out according to a randomized, double-blind, double-dummy, five-way crossover design over a 9-week period. All subjects received 1 week of treatment with the following, in randomized order, with a washout week between each treatment: budesonide Easyhaler 800 microg day(-1) plus placebo Turbuhaler; budesonide Easyhaler 1600 microg day(-1) plus placebo Turbuhaler; placebo Easyhaler plus Pulmicort Turbuhaler 800 microg day(-1); placebo Easyhaler plus Pulmicort Turbuhaler 1600 microg day(-1); placebo Easyhaler plus placebo Turbuhaler. The final inhalation of study drug was performed at the study centre, where blood and urine samples were collected. Fifteen subjects were recruited and all completed the study. Mean serum cortisol AUC0-20 values (the primary outcome variable) were comparable for each device at the two dose levels, and met the defined criteria for equivalence (90% CI 0.8-1.25 for between-treatment difference). Budesonide 800 microg day(-1) caused minimal suppression of serum cortisol AUC0-20 values, Budesonide 1600 microg day(-1) statistically significantly suppressed serum cortisol AUC0-20 values compared with placebo. Mean morning serum cortisol values were within the reference range in al treatment groups. At a budesonide dose of 800 microg day(-1) mean urine cortisol/creatinine ratio was statistically significantly higher with Easyhaler than with Turbuhaler, but there was no significant difference between the devices at the 1600 microg day(-1) dose. Serum budesonide concentrations were equivalent for each device at both dose levels. Adverse drug reactions were infrequent and mild in nature and there were no clinically significant changes in laboratory safety variables. In conclusion, in healthy male volunteers, budesonide 800 microg day(-1) and 1600 microg day inhaled from Easyhaler had comparable systemic effects to the same doses inhaled via Turbuhaler.
650    02
$a mladiství $7 D000293
650    02
$a dospělí $7 D000328
650    02
$a analýza rozptylu $7 D000704
650    02
$a antiastmatika $x aplikace a dávkování $x farmakologie $7 D018927
650    02
$a plocha pod křivkou $7 D019540
650    02
$a budesonid $x aplikace a dávkování $x farmakologie $7 D019819
650    02
$a interval spolehlivosti $7 D016001
650    02
$a kreatinin $x moč $7 D003404
650    02
$a klinické křížové studie $7 D018592
650    02
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    02
$a dvojitá slepá metoda $7 D004311
650    02
$a design vybavení $7 D004867
650    02
$a lidé $7 D006801
650    02
$a hydrokortison $x krev $7 D006854
650    02
$a mužské pohlaví $7 D008297
650    12
$a nebulizátory a vaporizátory $7 D009330
650    02
$a terapeutická ekvivalence $7 D013810
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a srovnávací studie $7 D003160
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Granander, M.
700    1_
$a Toivanen, P.
700    1_
$a Malinen, A.
773    0_
$t Easyhaler $g (2006), s. nestr. $w MED00151815
773    0_
$t Respiratory medicine $x 0954-6111 $g Roč. 95, č. 11 (2001), s. 863-869 $w MED00004105
856    41
$u http://ac.els-cdn.com/S0954611101911576/1-s2.0-S0954611101911576-main.pdf?_tid=66a0389e-840e-11e3-a245-00000aab0f01&acdnat=1390468493_69526b8a16cec9041a53b56a3c39680e $y plný text volně přístupný
910    __
$a ABA008 $b DT 10445 $b A 617 $y 4 $z 0
990    __
$a 20140123094424 $b ABA008
991    __
$a 20140124084753 $b ABA008
999    __
$a ok $b bmc $g 1007838 $s 841701
BAS    __
$a 5 $a 4
BMC    __
$a 2006 $d nestr. $m Easyhaler $x MED00151815
BMC    __
$a 2001 $b 95 $c 11 $d 863-869 $i 0954-6111 $m Respiratory medicine $n Respir Med $x MED00004105
LZP    __
$a NLK 2014-01/jtme

Najít záznam

Citační ukazatele

Možnosti archivace